What is Peptyde Bio?
Peptyde Bio operates as a specialized Agtech enterprise, leveraging deep-rooted expertise in plant science to engineer novel AMPs. Launched by the Danforth Technology Company, a subsidiary of the Donald Danforth Plant Science Center, the firm serves as a commercial bridge for advanced laboratory research. By utilizing a collaborative business model that emphasizes joint development and licensing agreements, Peptyde Bio effectively mitigates the risks associated with early-stage biotech commercialization. The company is led by a veteran team with extensive experience in managing high-growth Agtech ventures, ensuring that its scientific output is aligned with the practical needs of global agricultural partners.
How much funding has Peptyde Bio raised?
Peptyde Bio has raised a total of $1.2M across 1 funding round:
Other Financing Round
$1.2M
Other Financing Round (2022): $1.2M with participation from BioGenerator Ventures, QRM Capital, Danforth Technology Company, and St Louis Arch Angels
Key Investors in Peptyde Bio
St Louis Arch Angels
A network of accredited investors dedicated to funding early-stage businesses in the St. Louis region, focusing on fostering economic growth through strategic capital deployment.
QRM Capital
A private investment firm that provides financial backing and strategic guidance to high-potential companies, often focusing on long-term value creation.
BioGenerator Ventures
A venture capital firm specializing in early-stage biotech and life sciences, providing both capital and operational support to bridge the gap between research and commercialization.
What's next for Peptyde Bio?
With this major enterprise-level funding, Peptyde Bio is poised to scale its operational capacity and expand its portfolio of intellectual property. The strategic focus will likely shift toward deepening industry partnerships and accelerating the transition of its AMP candidates from the research phase to field-ready applications. By leveraging the support of its institutional backers, the company aims to solidify its role as a primary provider of sustainable agricultural solutions, addressing critical challenges in crop protection and plant health. Future growth will be defined by the successful execution of its licensing strategy and the continued validation of its technology within the broader agricultural ecosystem.
See full Peptyde Bio company page
